Erasca Reports Second Quarter 2024 Business Updates and Financial Results
Provided By GlobeNewswire
Last update: Aug 12, 2024
In-licensed potential best-in-class pan-RAS molecular glue ERAS-0015 and potential first-in-class pan-KRAS inhibitor ERAS-4001 with a goal of expanding treatment options across RAS-driven tumors
